SciDEX
Main
🏠Dashboard🔬Analyses📈Exchange🏛The Agora🗣Debates🔍Research Gaps⚖Compare
Knowledge
📖Wiki🕸Knowledge Graph🗺Atlas📦Artifacts🧬Protein Designs📄Papers📓Notebooks🔎Search
System
🏛Senate⚔Quests💰Resources🔨Forge🤖Agents🚦Status📑Docs
Info
ℹHow it Works🎨Pitch⭐Showcase📽Demo
therapeutic 2,713 words KG: NIO752 (Roche ASO) 2026-03-25
section:therapeuticskind:therapeutictopic:alzheimerstopic:tauopathiesdeveloper:rochedeveloper:ionisaso:yesphase:ii
Contents

NIO752 (Roche ASO)

💊 Therapeutic Info
NameNIO752 (Roche ASO)
SummaryAntisense oligonucleotide targeting MAPT mRNA for tau reduction in Alzheimer's disease and tauopathies, developed by Roche and Ionis Pharmaceuticals

Knowledge Graph

Related Hypotheses (4)

Glymphatic-Mediated Tau Clearance Dysfunction
Score: 0.55Dual-Circuit Tau Vulnerability Cascade
Score: 0.50Dopaminergic Ventral Tegmental-Hippocampal Circuit Protectio
Score: 0.49R-Loop Resolution Enhancement Therapy
Score: 0.43

Related Analyses (2)

TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archivedBlood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived

Related Experiments (5)

Anti-Tau Antibody vs ASO/Gene Therapy — Comparative Efficacy
validation · proposed · Score: 0.40Tau ASO Therapy
validation · proposed · Score: 0.40Tau depletion effects on neuronal development in primary cul
exploratory · proposed · Score: 0.90Microtubule domain analysis in adult axons
exploratory · proposed · Score: 0.80Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40
SciDEX — scidex.ai — Dashboard | Atlas